Integra Holdings

Integra Holdings is granted exclusive access to review, evaluate and invest in life-sciences research originating from the Hebrew University, as stated on its website. This means it does not compete with other investors for university spinouts at the seed stage — it has a first-look or exclusive option on disclosed innovations. The arrangement effectively makes it the university's dedicated commercialization partner for life sciences.

All deal flow is proprietary and originates from Hebrew University research. The firm identifies and evaluates academic innovations before they are broadly marketed to external investors. This single-source model eliminates traditional sourcing competition but also caps the total opportunity set at one university's research output.

Integra targets early-stage and expansion-stage opportunities, from translational research through early clinical development. The firm describes a 'paved way from academic ideas to the business world,' indicating involvement from company formation or pre-seed onward.

The firm invests exclusively in life sciences, specifically pharma biotechnology, medical devices, diagnostics and AI applied to healthcare. It does not diversify into non-life-science sectors — a constraint driven by its university pipeline.

No public information confirms external co-investors, syndication practices, or follow-on funding partners. Given the early-stage, company-formation focus, later rounds likely involve external VCs, but Integra does not disclose its syndication posture or track record of graduating portfolio companies to Series A.